Prostate Cancer | Specialty

The OncLive Prostate Cancer condition center page is a comprehensive resource for clinical news and expert insights on how to approach treatment for patients with nonmetastatic, castration-resistant, or castration-sensitive prostate cancer. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, ongoing research, and treatment advances with androgen receptor inhibitors, PARP inhibitors, and more in prostate cancer.

Dr. Chi on Combinations with Androgen Deprivation Therapy for Prostate Cancer

July 7th 2017

Kim Chi, MD, associate director of clinical research, Vancouver Prostate Centre, professor, Department of Medicine, University of British Columbia, discusses combinations with androgen deprivation therapy for patients with prostate cancer.

Dr. Stephenson on Patient Preferences on Undergoing Active Surveillance for Prostate Cancer

July 6th 2017

Andrew Stephenson, MD, director of Urologic Oncology, Cleveland Clinic, discusses patient preferences with undergoing active surveillance versus active treatment for their prostate cancer.

Dr. Higano on Radium-223 for Prostate Cancer

June 27th 2017

Celestia Higano, MD, professor of Medicine and Urology at the University of Washington, and a member of the Clinical Research Division at Fred Hutchinson Cancer Research Center, discusses radium-223 for patients with prostate cancer.

Dr. Sartor on the Implications of the Analysis of Sipuleucel-T in Prostate Cancer

June 27th 2017

Oliver Sartor, MD, a medical oncologist at the Tulane University School of Medicine, discusses the implications of the analysis of African-American patients receiving sipuleucel-T (Provenge) compared with Caucasians with metastatic castration-resistant prostate cancer.

Future Directions in Treating Advanced Prostate Cancer

June 26th 2017

Radium-223 in Combination Therapy for mCRPC

June 26th 2017

Radium-223 in mCRPC

June 26th 2017

Future of PARP Inhibitors in mCRPC

June 26th 2017

AR-V7 Testing in mCRPC

June 26th 2017

Sequencing and Layering of Drugs in CRPC

June 26th 2017

Radiation Therapy and ADT in CRPC

June 26th 2017

Abiraterone and Chemotherapy in CRPC

June 26th 2017

Combination Therapies in Localized Prostate Cancer

June 26th 2017

Active Surveillance in Prostate Cancer

June 26th 2017

Molecular Testing in Prostate Cancer

June 26th 2017

Genetic Testing in Prostate Cancer

June 26th 2017

Heritable Prostate Cancer: Germline vs Somatic Mutations

June 26th 2017

Active Surveillance Retains Critical Role in Prostate Cancer Care

June 26th 2017

Andrew Stephenson, MD, discusses some of the past and current data demonstrating the benefits of active surveillance for patients with localized prostate cancer and the evolving opinions on PSA screening.

Uses of MRI Testing in Prostate Cancer

June 23rd 2017

Andrew Vickers, PhD, attending research methodologist at Memorial Sloan Kettering Cancer Center, discusses some potential uses of MRI testing for patients with prostate cancer.

Dr. Stephenson on the Impact of Active Surveillance in Prostate Cancer

June 23rd 2017

Andrew Stephenson, MD, director of Urologic Oncology, Cleveland Clinic, discusses the impact of active surveillance on the field of prostate cancer.